Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Fall 2021 RFP: Outcome Measures, 2021
    Exploring the Role of Faulty Protein Degradation as a Cause of Parkinson’s Disease

    Study Rationale: For the brain to work efficiently, its cells have systems to clear out old proteins that are no longer needed or functional. When these protein-clearing systems fail, old proteins...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Development of an Inhibitor of Tau Aggregation to Treat Parkinson’s Disease

    Study Rationale: The formation of tau aggregates is caused by excessive modification and abnormal folding of the tau protein in the brain, which leads to cellular dysfunction and neurodegeneration...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Preclinical Studies of Compounds that Block Alpha-synuclein Aggregation by Antagonizing the Sigma-2 Receptor

    Study Rationale: There is a dire need to discover and develop novel therapeutics for Parkinson’s disease (PD), a disorder for which no disease-modifying therapies exist. Targeting the sigma-2 receptor...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Investigating the Neuroprotective Potential and Mechanism of Action of an Inhibitor of the Rho-associated Protein Kinase (ROCK)

    Study Rationale: Altered signaling through the Rho-associated protein kinase (ROCK) pathway has been found to play a role in the cellular pathogenesis of Parkinson’s disease (PD). Previously, we...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Modulation of Glycine for the Treatment of Parkinson’s Disease

    Study Rationale: Levodopa, currently the best treatment for the symptoms of Parkinson’s disease (PD), eventually leads to the development of uncontrollable involuntary movements, called dyskinesia. In...

  • Research Grant, 2021
    Evaluation of Digital Mobility Data to Identify Individuals at Risk of Developing Parkinson’s Disease

    Study Rationale: Gait disturbances play a major role in the motor manifestation of Parkinson’s disease (PD). Traditional clinical assessments aimed at measuring motor deficits do not sufficiently...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.